Timothy Warbington’s Post

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is advancing innovative solutions to address one of the most widespread health issues—chronic lower back pain. Our ADAPT clinical trial leverages CELZ-201-DDT for the treatment of Degenerative Disc Disease, targeting the root causes of pain rather than merely managing symptoms.   With 70% of adults experiencing lower back pain in their lifetime, current treatments often fail to address the underlying degeneration of intervertebral discs. ADAPT offers a regenerative approach that aims to change this narrative, providing hope for improved quality of life.   Learn more about our progress - https://lnkd.in/df9jcNii #creativemedical #celz #biotech

Here’s a close-up look at the S.T. Genesis device, a small yet powerful tool for opioid withdrawal relief. This drug-free, cutting-edge device by Speranza Therapeutics uses non-invasive nerve stimulation to alleviate symptoms, offering a new level of support for those on the path to recovery. The size comparison shows how discreet and easy-to-use it is—designed to help individuals regain control without adding more challenges to their journey. The S.T. Genesis empowers both patients and providers in tackling one of today’s most pressing health issues. Learn more here: https://lnkd.in/eFak_G9D #recovery #technology #innovation #hope #addictionmedicine #sobriety

Clot chronicity, that is, how the consistency of the clot changes as it ages, from a soft red blood cell-rich gob to a tough mass made of fibrin and collagen that adheres tightly to the vessel wall (the clot continuum is clinically categorized as acute, subacute, and chronic), would dictate a variety of removal strategies. Today, there are several on-label drug and thrombectomy strategies (see Figure 3). Devices for deep venous disease are having their day; the markets are becoming crowded. Second-generation movers must now find meaningful ways to differentiate themselves. MedTech Strategist interviews two companies with outside-the-box solutions: SonoVascular, Inc., in venous thrombectomy, and Auxetics, the developer of a novel venous stent. Part 2 of a 2-part review of the deep venous device market: https://bit.ly/3Vqn7XM #medtech #thrombectomy #deepvenous #venous

The path of breaking free from opioid use is never easy, and the fear of withdrawal can often feel overwhelming. At Speranza Therapeutics, we understand the emotional and physical challenges this brings. The S.T. Genesis device offers a safe and effective way to manage withdrawal symptoms, empowering patients to detox without fear. By targeting the body’s nervous system, it provides relief during the hardest part of the recovery journey. If you or someone you know is looking for a smoother path to recovery, discover how the S.T. Genesis can help. #recovery #hope #addictionmedicine #healthcare #innovation #technology

A big thank you to Cystic Fibrosis Trust for sharing this exciting update! Recent clinical trials show that a new triple combination modulator therapy, ‘Vanza Triple’, could offer additional benefits for some people with cystic fibrosis (CF) compared to Kaftrio. 🔎 Developing better modulator therapies is crucial to provide more treatment options and help more individuals with CF experience improved health outcomes. Find out more about Vanza Triple and what it could mean for the CF community by reading the full article here: https://lnkd.in/g9d7fMW3 #CysticFibrosisAustralia #CFA #VanzaTriple #Kaftrio #CysticFibrosis #CFResearch #CysticFibrosisAwareness

A team of US researchers sought to evaluate the impact of discontinuing both hypertonic saline (HS) and dornase alfa (DA) after starting treatment with Trikafta. Participants in the SIMPLIFY study who sequentially discontinued both HS and DA experienced no meaningful changes in clinical outcomes and reported decreased treatment burden compared with those who remained on both therapies. The results of the study continue to inform a new era of postmodulator care of people with CF. Learn More: https://lnkd.in/ghcjnrfJ #CFNews #Research #CFResearch #CysticFibrosis

Developing a Parkinson’s disease drug comes with important questions. Will it be safe and effective? Will it be free from significant side effects? 🤔 Our globally renowned scientific and medical teams are here to support you in building a robust development strategy tailored to answer your questions -- no matter where your drug is in its trial journey. ➡ Watch our on-demand webinar to learn how. https://lnkd.in/d9ts99XD #ClarioNeuroscience #ClinicalTrials #ParkinsonsDisease #DrugDevelopment

As Multiple Sclerosis Awareness Month comes to an end, it's important to recognize the impact of this disease that affects millions worldwide. Treatments like Ocrelizumab have become beacons of hope, improving the quality of life for many. But how do we ensure these advancements are accessible to all who need them? The Lyfegen Agreements Library is key: housing over 4'500 agreements, with 120+ agreements on Multiple Sclerosis, it stands as the world's largest repository of innovative pricing models and public drug pricing agreements. This resource empowers pharma companies to navigate the complexities of making critical treatments available to patients. Find out more on lyfegen.com/library #MultipleSclerosisAwareness #InnovationInHealthcare #LyfegenAgreementsLibrary #Ocrelizumab

Hey Mike! I have also experienced a case like this. Here is the short synopsis: 36 y/o male, distal patellar tendon insertional tear at the tibial tuberosity. Proximal to the distal insertion the tendon measured about .3cm and did not have any thickenning or signs of tendinopathy. Tx: 60cc of BMA form PSIS/ obtained 4cc of BMC using Emcyte Pure System. Injection was USG precisely at the distal insertion. Within 3 weeks, began having more pain, f/up ultrasound showed new diffuse tendinopathy on subsequent ultrasound imaging. Tendon thickness increased to about 1.2cm. He was treated with subsequent PT and shockwave and ended up doing ok. My question to the group is : Was as a direct consequence of the biologic injection or were the wheels already in motion towards tendinopathy and we just pushed it over the edge?